Weaponising truly individualised therapies

The neoantigen-based therapeutic industry has seen a huge explosion this year in terms of excitement and investment. As this nascent and emerging industry develops, critical questions are unfolding that need answering to ensure therapeutic success.

The Neoantigen Summit Europe is the only industry-led meeting dedicated to the robust prediction, identification and validation of neoantigens to develop potent tumorigenic immune responses.

Join over 150 of the leading minds in this industry such as Gritstone Oncology, BioNtech, Genocea, 3T Biosciences and Genentech as we discuss the end-to-end development of individualised neoantigen vaccine and cell-based immunotherapies.

Navigate two tracks of content from defining and characterising the best epitopes to reviewing the pros and cons of the various therapeutic modalities of choice.

Take part in stimulating discussions around shared and personalised neoantigens and realise the potential for neoantigens to create truly individualised cancer therapeutics.

Join us this April and be a part of this movement to help bring these emerging therapeutics to market.


Snapshot of Our World Class Speaker Faculty

Andrew Allen



Jennie Lill

Senior Director of Proteomics & NGS


Jessica Flechtner



Wigard Kloosterman

Chief Scientific Officer

Frame Cancer Therapeutics

Agnete Fredriksen

President & Chief Scientific Officer


Dolores Schendel



Luke Lee

CEO, Co-Founder

3T Biosciences

Ray Jupp

Chief Scientific Officer

Ervaxx LTD

Hear What Past Neoantigen Summit Attendees Have To Say:

"The relevance of neoantigens in the clinical efficacy of immunotherapy is beyond doubt. However, several fundamental and practical questions remain unanswered and this meeting is an opportunity to discuss these issues with experts of the field"

Alexandre Harari, Group leader, Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, Lausanne

"Targeting neoantigens will be the next wave of cellular therapy. I have very high expectations on the clinical activity of neoantigen directed therapies!"

Joost van den Berg, Head of Facility Pharmacist, Netherlands Cancer Institute

Confirmed Sponsors

NEC OncoImmunity
CEM Corporation
Logo1 BCN Peptides 300dpi